IceCure’s ProSense® System First and Only Medicare Approved Cryoablation Procedure for Breast Cancer

 

Cryoablation technology company, IceCure Medical (Nasdaq: ICCM) has received assignment to a Medicare Payment Group for hospital outpatient payment for its ProSense® System.

ProSense is a minimally-invasive procedure that destroys early-stage breast cancer tumors by cryoablation (freezing).

In October, IceCure filed a De Novo classification request with the FDA for breast cancer marketing authorization for early-stage low-risk breast cancer patients at high risk for surgery.

 Highlights

  • IceCure’s cryoablation procedure significantly reduces the cost burden of treatment, and the impact on patients, as compared to current standard of care lumpectomy procedures.
  • IceCure’s ProSense breast cancer cryoablation procedures have been assigned CPT Category III code 0581T to ambulatory payment classification 5091, Level 1 Breast/Lymphatic Surgery and Related Procedures.
  • The payment assignment begins on January 1, 2023, opening the potential for facilities to be paid for these procedures subject to the Company’s receipt of FDA marketing authorization of ProSense for breast cancer.

IceCure’s mission is to provide women facing breast cancer with state-of-the-art optimized, minimally invasive technology that destroys tumors and allows them to walk out of the procedure room and return to a cancer-free life.

Share This Article

 

About the Author

IceCure’s ProSense® System First and Only Medicare Approved Cryoablation Procedure for Breast Cancer

Editor Prism MarketView